Reimbursement based on stratified, rather than whole-population, cost-effectiveness analysis has indeed been shown to lead to a more efficient use of healthcare when prices are fixed.
There are several types of pharmacoeconomic evaluation: cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis and cost-utility analysis.
This cost-effectiveness analysis was based on data from a recent cohort study, which had compared medical outcomes associated with different planned locations for low risk births.
A cost-effectiveness analysis found that dabigatran was more effective than warfarin for prevention of stroke in patients with atrial fibrillation and a history of prior stroke or transient ischemic attack.
